Additionally, CS treatment primarily involves corticosteroids and immunosuppressive agents to reduce inflammation and control disease progression, although biologics such as tumor necrosis factor-alpha (TNF-α) inhibitors are considered in refractory or steroid-dependent cases. This evidence concerns the gene TNF and Cowden syndrome 1.